Both p21ras and phosphatidylinositol 3-kinase are critical elements in signaling pathways mediating insulin/IGF-I induced cell cycle progression. For example, microinjection of antibodies, peptides, or recombinant proteins which block the interaction of the SH2 domains of the PI 3-k p85a subunit with tyrosine phosphorylated intracellular targets blocks insulin mediated DNA synthesis. We report here that this inhibitory phenotype is observed whether the injections are made into quiescent cells (the standard approach), or at any time point during G 1 phase subsequent to stimulation. This observation is not true, however, for the major substrate of the insulin/ IGF-I receptor (IRS-1) despite the well known interaction of p85 with IRS-1. Antibodies to IRS-1 are inhibitory only when injected during the ®rst 15 min of G 1 phase, as are antibodies to another major IRS-1 binding protein, the tyrosine phosphatase SHP2. We also have microinjected reagents which target proteins involved in the formation of rasGTP and which mediate some of the downstream eects of ras activation. Reagents which target the formation of rasGTP (Shc and dominant negative ras protein) inhibit DNA synthesis only at points early in G 1 , as do reagents which target components of the MAP kinase pathway. Injection of antibodies to p21ras itself, or a recombinant Raf-1 protein domain which binds to the eector region of ras in a GTP-dependent manner, results in the inhibition of cell cycle progression throughout G 1 phase. The results point to a continuous requirement for both PI 3-k and ras activity until cellular commitment to DNA synthesis, although some of the molecules which are both upstream and downstream of these activities are only required transiently. Our results are also consistent with a Raf-1 independent ras activity late in G 1 , as well as IRS-1 independent eects of PI 3-kinase.
Introduction
Insulin/IGF-I action is initiated by receptor autophosphorylation and activation, followed by the tyrosine phosphorylation of intracellular substrates. A principle substrate of the receptor is insulin receptor substrate-1 (IRS-1) (White et al., 1985; Sun et al., 1993) . In response to insulin, this protein is phosphorylated on multiple tyrosine residues, which acts as a trigger for the recruitment of and interaction with a number of dierent src homology 2 (SH2) domain containing proteins (reviewed in White, 1994) . The amino acid sequence around the phosphorylation sites of IRS-1 determines the speci®city of these interactions, and results in the engagement of a de®ned cohort of proteins to the complex (Songyang et al., 1993) . These interactions may in part determine the speci®city of insulin/IGF-I signaling. Several SH2 domain-containing proteins have now been identi®ed which bind to tyrosine phosphorylation IRS-1. These proteins include Grb2, an adaptor molecule involved in the regulation of p21ras (Lowenstein et al., 1992; Li et al., 1993) ; SHP2, a tyrosine phosphatase also known as Syp or SH-PTP2 (Adachi et al., 1996; Feng et al., 1994) ; and the adaptor proteins p85 (Myers et al., 1992; Piccione et al., 1993) and Nck . The interaction of p85a with IRS-1 results in the activation of the catalytic activity of phosphatidylinositol 3-kinase, present in a heterodimeric complex with p85 (Myers et al., 1994) . Recent studies have shown that the activity of PI 3-kinase is required for both the mitogenic and metabolic activities of insulin/IGF-I in mammalian cells. (Jhun et al., 1994b; Haruta et al., 1995; Quon et al., 1995) .
The presence of Grb2 in the IRS-1 signaling complex also provides the potential for the activation of p21ras Lowenstein et al., 1992; Olivier et al., 1993; Skolnik et al., 1993) . Ras is required for insulin/ IGF-I mediated cell cycle progression and gene expression (Jhun et al., 1994a) , although it appears not to be directly involved in glucose transport (Haruta et al., 1995; Quon et al., 1995) . p21ras is activated by the exchange of bound GDP for GTP, an event catalyzed by guanine nucleotide exchange factors. One such factor is the mammalian homologue of the Drosophila son of sevenless gene product mSOS (Rozakis-Adcock et al., 1993; Skolnik et al., 1993; Chardin et al., 1993; Baltensperger et al., 1993) . This protein is found in a complex with Grb2, thus the association of Grb2 with IRS-1 may be important in ras guanine nucleotide exchange. However, the major pathway to ras activation in response to insulin/IGF-I appears to be mediated by Shc, another adaptor molecule which becomes tyrosine phosphorylated in insulin stimulated cells (Pelicci et al., 1992) . Shc possesses both an SH2 domain and a novel non-SH2 phosphotyrosine binding domain (Pelicci et al., 1992; Kavanaugh et al., 1995) . This latter domain appears to be of primary importance to insulin and IGF-I signaling (Sasaoka et al., 1994c; Ricketts et al., 1996) . The tyrosine phosphorylation of Shc results in the SH2 domain mediated association of Grb2/mSOS with the protein, and appears to be an essential event in insulinstimulated ®broblasts leading to p21ras activation (Salcini et al., 1994) . rasGTP then recruits Raf-1 kinase to the plasma membrane where it is activated, leading to the activation of the MAP kinase cascade, and to immediate early gene expression.
Although many of the components necessary for insulin-mediated mitogenesis have now been identi®ed, the temporal relationships involved in their activation have not been well de®ned. In this study, we have examined at what points early in the cell cycle various signaling molecules are required for DNA synthesis to occur. Utilizing microinjection of neutralizing reagents into living ®broblasts at multiple points during G 1 phase of the cell cycle, we have de®ned transient roles for proteins which have previously been shown to function both upstream and downstream of p21ras, although rasGTP itself appears to be required until commitment to DNA synthesis. In addition, we ®nd that targeting and activity of PI 3-kinase are required for DNA synthesis throughout all stages of the G 1 phase. This result is obtained despite the apparent transient requirement for the major insulin-induced p85 binding protein, IRS-1.
Results
We have used the technique of single cell microinjection as a means to introduce into living cells reagents which inhibit the normal activity and/or localization of signaling proteins in vivo. In this study, injections were performed throughout the G 1 phase of the cell cycle. The cells used in most of these experiments are Rat-1 ®broblasts stably transfected with human insulin receptors (McClain et al., 1987) which respond to insulin and IGF-I as mitogens, i.e. they undergo immediate early gene expression and cell cycle progression, and BrdU labeling studies have shown that the cells begin S phase transition, marked by the synthesis of a new complement of DNA, at approximately 12 h following the addition of insulin.
Microinjection of reagents directed against IRS-1 and associated proteins
We have previously shown that microinjection of anti-IRS-1 antibody inhibits subsequent insulin and IGF-I induced mitogenesis . To examine whether IRS-1 plays an essential role in signal transduction at later times during G 1 , we microinjected Figure 1 Eect of microinjected reagents on DNA synthesis. (a), HIRcB cells were serum starved for 36 ± 48 h and microinjected either prior to stimulation of the cells with insulin (0) or 15 min following stimulation (15). Cells were injected with an anity puri®ed polyclonal antibody raised against the amino terminus of IRS-1 (5 mg/ml), or an anity puri®ed polyclonal antibody raised against SHP2 phosphotyrosine phosphatase (4 mg/ml). The cells were then labeled overnight with BrdU and ®xed for immunostaining. Results were analysed and photography was performed on an Axiophot epi¯uorescence microscope equipped with separate ®lters for the contrasting¯uorescent probes used. Injected cells were identi®ed by cytoplasmic FITC staining and then individually scored for BrdU incorporation, denoted by rhodamine stained nuclei. Bars represent the mean+s.e. of three independent experiments in which HircB cells were injected with the indicated reagents. BrdU incorporation into newly synthesized DNA was then quantitated as described in . Approximately 1000 total injected cells were evaluated in each case the same inhibitory antibody at various times after stimulation of the cells with insulin. The results of the injection were monitored by BrdU labeling, followed by immuno¯uorescence staining and analysis . Representative results of this staining method are shown in Figure 5 . In this example, the cells were stained with a rat monoclonal anti-BrdU antibody and this staining was then visualized with a TRITCconjugated donkey anti-rat IgG antibody (red nuclei). Injected cells were unambiguously identi®ed with FITCconjugated donkey anti-rabbit IgG (cells with GREEN cytoplasm). Quiescent cells demonstrated nuclear staining in 24% of the cells and treatment of the cells with 100 ng/ml insulin resulted in 82% of uninjected or preimmune IgG injected cells demonstrating nuclear BrdU staining. Injection of the IRS-1 antibody into HIRcB cells which were insulin treated 1 h later reduced the number of positive cells to 27% (Figure 1 ). On the other hand, when the antibody was injected 15 min following insulin stimulation, no inhibitory eect on BrdU incorporation was observed.
A similar experiment was carried out with a monoclonal antibody raised against the tyrosine phosphatase SHP2. This enzyme binds to IRS-1 at a speci®c phosphotyrosine residue, and its catalytic activity is increased as a result of this interaction (Pluskey et al., 1995) . We and others have previously shown that SHP2 is a required positive mediator of insulin/IGF-I signaling (Xiao et al., 1994; Yamauchi et al., 1995; Milarski and Saltiel, 1994) . When the anti-SHP2 antibody was injected into quiescent HIRcB cells prior to insulin stimulation, it reduced BrdU incorporation to 34%, an inhibition of 78% compared to control injected cells. When the injections were performed 15 min after insulin addition, the inhibitory eect was no longer present (Figure 1 ), similar to the results obtained with anti-IRS-1 antibody.
PI 3-kinase activity is required throughout G 1 Several groups, including our own, have shown that PI 3-kinase is necessary for gene expression and DNA synthesis in response to insulin (Yamauchi et al., 1993; Jhun et al., 1994b) . We now examined the role of PI 3-kinase at later points in the cell cycle by the delayed microinjection of an anity puri®ed anti-p85 antibody and a recombinant N-terminal SH2 domain of the p85a subunit of the enzyme. As shown in Figure 2 , microinjection of the anti-p85 antibody before insulin addition resulted in complete inhibition compared to basal levels of DNA synthesis. In contrast to the previous results with anti-IRS-1 and anti-SHP2, the antibody against p85a showed the same inhibitory phenotype when injected 15 min after insulin addition. Likewise, when the N-terminal SH2 domain was injected prior to addition of insulin, it caused a complete blockade of DNA synthesis. When injected after stimulation, the fusion protein retained its inhibitory phenotype (Figure 2 ). Control injections of GST alone were not inhibitory even at high concentrations of the protein (Sasaoka et al., 1994c) , whether conducted prior or subsequent to stimulation of the cells with insulin. As an additional control, microinjection of other SH2 domain fusion proteins not relevant to insulin signaling (GST-Shc SH2 and GST-GAP SH2) were found to have no inhibitory eect (Jhun et al., 1994b) when injected at various time during G 1 (data not shown). These results indicate that p85a SH2 domain interaction is required for a longer period of time than the function of IRS-1 itself. They also raise the possibility that the interaction of p85a with phosphotyrosine residues of a protein other than IRS-1 are critical to this later function. An extended time course of microinjections following insulin stimulation of the cells is shown in Figure 2 . These manipulations were conducted at 2 h invervals following insulin addition throughout G 1 and extending into S phase. In addition, one set of coverslips was treated with the PI 3-kinase inhibitor wortmannin (100 nM). Each of the microinjections and treatment with wortmannin abolished DNA synthesis to a similar extent (essentially total inhibition) at every time point during G 1 that was tested. As the cells advanced into S phase between 12 and 14 h after insulin addition, the inhibition no longer occurred. The lack of repression of DNA synthesis at these later time points seems to indicate that the injected reagents and treatment with wortmannin are not simply toxic to the cells. Earlier studies also showed that injection of anti-p85 or the p85 SH2 fusion protein did not block serum stimulated DNA synthesis (Jhun et al., 1994b) . Taken together, these results are consistent with a continuous essential role of p85 SH2 domain interaction and PI 3-kinase enzymatic activity throughout G 1 .
Since the above results with wortmannin appear to indicate that the enzymatic activity of PI 3-kinase is required throughout G 1 , we assessed the levels of PI 3-kinase activity in cell extracts prepared from insulin stimulated HIRcB cells. Measurement of PI 3-kinase activity in phosphotyrosine antibody precipitates demonstrated a pronounced peak of activity within 5 min of insulin stimulation (7.2-fold). This peak of activity gradually decreased over the course of 8 h (Figure 3 ), but remained at a level which was higher than basal throughout this time period. Results obtained with anti-p85 were similar, with slightly less peak activity and residual activity which persists through all time points examined. These results indicate that PI 3-kinase activity remains elevated above basal levels for a longer period of time than previously appreciated. The microinjection results suggest that this elevated activity may be required for cell cycle progression to occur. 
Microinjection of reagents directed against components of the ras/MAP kinase pathway
Insulin treatment of cells leads to the phosphorylation of Shc, which then couples to the grb2/SOS complex, leading to the formation of p21rasGTP which is essential for insulin-induced DNA synthesis (Sasaoka et al., 1994c) . We examined the temporal relationships between components of this activation pathway using the delayed injection approach described above. A monoclonal antibody which recognizes the eector domain of p21ras (Y13-259) was microinjected into HIRcB cells and DNA synthesis was monitored. This antibody inhibited cell cycle progression when injected prior to insulin treatment as well as 15 min and 2 h following insulin treatment (Figure 4) . We then used the same approach to examine events upstream of p21ras activation by injecting a recombinant dominant negative point mutant of Hras (asparagine 17). When injected into quiescent cells, the recombinant N17 protein inhibited insulin-stimulated DNA synthesis greater than 90% (Jhun et al., 1994a and Figure 4) . The N17 protein also inhibits DNA synthesis to approximately the same extent when injected 15 min after insulin treatment. However, 2 h after addition of insulin, it had no eect upon insulin stimulated DNA synthesis ( Figure 4) .
We then used the same approach to examine Shc function. An anity puri®ed antibody directed against residues (125 ± 205 (Pelicci et al., 1992) , including part of its SH2 domain, was microinjected. When this antibody was injected into quiescent cells, it abrogated DNA synthesis completely (Figure 4) , reiterating the essential role of Shc in insulin mediated signal transduction. Microinjection of the same antibody 15 min following insulin stimulation, however, was without eect upon cell cycle progression. This observation appears to be consistent with the kinetics of Shc phosphorylation in insulin-treated cells, which reaches its maximum level within 15 min (Sasaoka et al., 1994a) .
Similar experiments were conducted to examine the function of the primary mediator of p21ras eects, Raf-1 kinase. A monoclonal antibody raised against a recombinant portion of the catalytic domain of the Raf-1 protein was used in these experiments (Kolch et al., 1990) . When this antibody was injected into quiescent cells, it completely abolished insulin-stimulated DNA synthesis (Figure 5a ). When injected 15 min after treatment with insulin, however, the inhibitory phenotype was no longer present. We performed a more precise kinetic analysis of the inhibition seen with this Raf-1 antibody. In these experiments, the cells were plated on etched coverslips on which cells injected during precise 1 min intervals can be speci®cally identi®ed. When the results of this type of experiment are viewed microscopically, a gradient of BrdU incorporation is observed over a 10 min interval. After approximately 10 min of insulin stimulation, the inhibitory eect of the antibody was Figure 4 Delayed injection of reagents which inhibit components of the ras/MAP kinase pathway. Bars represent the mean+s.e. of three independent experiments in which HircB cells were injected with the indicated reagents either before (0), 15 min following (0.25), or 2 h following (2) insulin stimulation. The cells were then labeled with BrdU, immunostained and analysed as in Figure 1 . At least 250 cells were injected in each experiment. The reagents used were injected at the following concentrations: anti ras, 2 mg/ml; ras dominant negative protein (N17) 3 mg/ml; anti Shc, 6 mg/ml; anti Raf-1, 3 mg/ml completely reversed. The same results were obtained when this experiment was conducted in NIH3T3 cells stimulated with 100 ng/ml IGF-I as illustrated in Figure 5a ± d, indicating similar kinetics of activation in these two cell lines using two dierent mitogens.
The physical interaction of Raf-1 with p21ras is well characterized, and the residues of each protein responsible for this essential interaction have been identi®ed (Chuang et al., 1994; Pumiglia et al., 1995) . The eector region of the ras protein binds to Raf-1 in a GTP dependent manner, and this interaction is a crucial step in the activation of Raf-1 kinase activity (Leevers et al., 1994) . A stable, high anity ras-binding region of Raf-1 has been mapped to the noncatalytic amino terminal domain of Raf-1 (Chuang et al., 1994) . We examined the importance of ras eector domain Figure 5 Dierent phenotypes obtained when delayed injection of Raf-1 antibody and dominant negative Raf-1 protein are compared. Quiescent NIH3T3 cells were microinjected with monoclonal anti-Raf-1 antibody. (a ± d) or puri®ed dominant negative Raf-1 protein (e ± h). Injections were carried out either prior to treatment of the cells with 100 ng/ml IGF-I (a and e), or at intervals following growth factor treatment. Delayed injections were performed at 1 min (b and f), 5 min (c and g), or 15 min (d and h) after IGF-I addition. The cells were labeled overnight with BrdU and then stained as before using a FITC-conjugated second antibody for the detection of injected cells. The double exposure photomicrographs shown here demonstrate which cells were injected (green cytoplasm) and which cells progressed to S phase in response to IGF-I (red/yellow nuclei). Bar represents 20 mm availability in later stages of G 1 by the delayed injection approach. A recombinant fusion protein comprising the initial 249 residues of Raf-1 kinase (including the ras binding domain but lacking any catalytic activity) was microinjected into HIRcB cells before and at intervals after insulin addition to the medium. The results of these experiments and a comparison to simultaneous results obtained with anti-ras antibody and dominant negative ras protein are presented in Figure 6 . The Raf-1 protein (raf/GNS) displayed a dominant negative phenotype when injected into quiescent cells 1 h prior to insulin stimulation. This protein would be expected to compete with endogenous ras eectors for binding to ras and thus prevent the activation of such eectors within the cell (Kolch et al., 1996) . Similar to anti-ras-antibody and in contrast to anti-Raf-1 antibody, microinjection of raf/ GNS resulted in the complete inhibition of DNA synthesis at all time points examined, both in HIRcB cells treated with insulin ( Figure 6 ) and in IGF-I-treated NIH3T3 cells (Figure 5e ± h ).
Discussion
A number of intracellular signaling proteins required for insulin/IGF-I-stimulated progression through G 1 phase of the cell cycle have now been identi®ed. Similar to other receptors possessing intrinsic tyrosine kinase activity, the insulin receptor appears to signal mitogenesis, at least in part, via the ras/MAP kinase pathway and through several SH2 domain-containing proteins. In this study, we have used single cell microinjection to introduce neutralizing reagents into living cells to block the normal activity and/or localization of known insulin signaling proteins. These injections have been carried out prior to mitogen stimulation of the cells and at various time points during G 1 phase of the cell cycle. This technique has permitted an examination of the kinetic relationships between these signaling molecules and has yielded several interesting observations.
IRS-1 and associated proteins
The antibody used in these experiments was raised against a recombinant protein consisting of amino acid residues 1 ± 224 of IRS-1 . This region contains a pleckstrin homology domain which may be important for the high anity interaction of IRS-1 with the insulin receptor (Myers et al., 1995) , as well as a phosphotyrosine binding domain (Kavanaugh et al., 1995; Craparo et al., 1995) which mediates the interaction of IRS-1 with the insulin receptor juxtamembrane domain (Craparo et al., 1995) . Thus, microinjection of this antibody prior to stimulation of the cells with insulin may result in impaired interaction of IRS-1 with the receptor, leading to reduced IRS-1 phosphorylation. The lack of inhibition observed when the antibody is injected 15 min following insulin stimulation may indicate that the interaction of IRS-1 with the insulin receptor is transient and that its required phosphorylation is accomplished within the Figure 6 Time course of delayed injection of ras-directed reagents. HIRcB cells were injected either before or at each of the indicated times after addition of insulin to the culture medium. Injections were carried out and analysed as in previous experiments. Data points re¯ect the mean+s.e. of three separate experiments in which at least 250 cells were injected at each time point. Puri®ed dominant negative Raf-1 protein was injected at a concentration of 2 mg/ml ®rst 15 min of the cell cycle. Alternatively, if this antibody also interferes with an intracellular function of IRS-1 after its phosphorylation, such as the proper activation and localization of IRS-1 binding proteins, this latter function of IRS-1 may be accomplished within the ®rst 15 min of G 1 . Because IRS-1 lacks intrinsic enzymatic activity, it is not possible to assess whether the delayed injection of the antibody neutralizes the biological activity of IRS-1 subsequent to its tyrosine phosphorylation in living cells. This is, in fact, one of the few major drawbacks of the otherwise very powerful microinjection approach. Because of the limited population of injected cells in these experiments, it is often dicult or impossible to evaluate biochemical consequences of antibody injection, unless a speci®c single cell assay can be devised. Our experiments evaluate the eect of the introduction of these reagents upon one marker of cell cycle progression, entry of the cells into S phase.
Delayed microinjection of anti-SHP2 antibodies yields results which are consistent with the view that at least some IRS-1 associated proteins function transiently. This phosphotyrosine phosphatase represents one of the major IRS-1 binding proteins in insulin treated cells (Kuhne et al., 1993; Sun et al., 1993; Sugimoto et al., 1994) . We have previously shown that SHP2 SH2 domain interaction is essential for cell cycle progression in this system (Xiao et al., 1994) , and Pessin and coworkers have blocked insulin-induced MAP kinase activation by transfection of catalytically inert SHP2 (Yamauchi et al., 1995) . How this enzyme functions in insulin/IGF-I signaling is still poorly understood, however, and the elucidation of the substrates of SHP2 will probably be necessary to clarify this issue.
In contrast to a transient role for IRS-1 and SHP2, the results obtained in this study with reagents directed against PI 3-kinase indicate that this enzyme plays a required role in insulin/IGF-1 signaling even at late stages of G 1 just prior to commitment to DNA synthesis. Thus, microinjection of antibodies raised against p85a, a recombinant p85 N-terminal SH2 domain fusion protein, or treatment of the cells with wortmannin, each inhibit BrdU incorporation at all times tested prior to initiation of DNA synthesis. These observations indicate that both the activity and the proper localization of PI 3-kinase are important for cell cycle progression to continue. This requirement may re¯ect a continuous need for PI 3-kinase metabolites in the cell. Alternatively, the same phenotype would be observed if a second required peak of PI 3-kinase activity occurred at a point late in G 1 prior to commitment of the cell to DNA synthesis. However, we were unable to detect such a late peak of activity. The residual PI 3-kinase activity which we ®nd by immunoprecipitation in late G 1 cell extracts is apparently required for DNA synthesis to occur. It is of interest that injection of the SH2 domain is inhibitory in this assay system at time points when earlier studies in the same cells have shown that IRS-1 is no longer detectably phosphorylated on tyrosine residues (McClain et al., 1987) . This is consistent with our own data showing that interference with IRS-1 15 min after insulin stimulation no longer inhibits DNA synthesis, whereas inhibition of PI 3-kinase even in late G 1 does. As such, these data dissociate the function of PI 3-kinase from IRS-1 activity shortly after insulin stimulation. Cantley and coworkers recently have shown (Rameh et al., 1995) that the SH2 domains of p85 are also capable of interaction with a metabolite of PI 3-kinase, phosphatidylinositol (3,4,5) trisphosphate. Injection of the SH2 domain fusion protein in our experiments may also interfere with a critical function of this metabolite. In any case, PI 3-kinase activity is increased above basal levels at all time points examined throughout G 1 , and this activity appears to be required for DNA synthesis to occur.
It has also recently been shown that PI 3-kinase possesses intrinsic serine protein kinase activity (Hunter, 1995) . In addition, PI 3-kinase appears to be the upstream mediator of the phosphorylation and activation of p70 S6 kinase (Weng et al., 1995; Monfar et al., 1995) . A recent microinjection study showed that antibodies against p70 S6 kinase inhibit DNA synthesis whether introduced into cells prior to serum stimulation or at later points during G 1 (Lane et al., 1993) . Our results appear to be consistent with these observations, and the requirement for persistent S6 kinase activation, perhaps to maintain ecient protein synthesis, may represent one reason why prolonged PI 3-kinase activity is required for DNA synthesis to occur.
ras/MAP kinase pathway
The results of our experiments also indicate that the activity of p21ras and the availability of the ras eector domain are required at later stages of G 1 , and that this later function is GTP dependent, but independent of Raf-1. These observations appear to be true despite data which show that molecules known to be upstream and downstream of ras are only required transiently, and that cellular rasGTP levels return to near quiescent levels within about an hour of stimulation (Langlois et al., 1994) in insulin-treated HIRcB cells. The functionally required rasGTP in later stages of G 1 must therefore represent a small fraction of total cellular p21ras protein. The required ras is also apparently sequestered from rasGAPs, because dominant negative ras protein, which competes for nucleotide exchange factors, is inhibitory only when injected in early stages of the cell cycle. In addition, microinjection of inhibitory Shc antibodies blocked insulin-induced DNA synthesis only transiently. The Shc antibody injected in our studies immunoprecipitates and recognizes on Western blots the 46, 52, and 66 kDa forms of the Shc protein. Immunoprecipitation experiments with this antibody have demonstrated the tyrosine phosphorylation of Shc, primarily the 52 kDa isoform, upon insulin/IGF-I treatment of HIRcB cells (Sasaoka et al., 1994c) . This phosphorylation event correlates temporally with the association of Grb2 and mSOS with the Shc protein in vivo. (Sasaoka et al., 1994b) . Our microinjection results are consistent with the kinetics of Shc phosphorylation in insulin-treated cells, which reaches its maximal level within 15 min, and con®rm the results obtained with dominant negative ras. Other studies using microinjection of dominant negative ras have indicated that the injection of this protein even after stimulation of the cells with serum can still block DNA synthesis. The dierence between this result and those presented here is possibly explained by the manner in which the ras pathway is utilized by insulin/IGF-1. We have previously shown, for in-stance, that the phosphorylation and utilization of Sch by both insulin and IGF-1 receptors is mechanistically dierent than for either EGF or serum. The dierence in phenotype observed in our experiments when anti-ras and N17 ras are compared probably are a re¯ection of the dierence in the intracellular targets of these reagents. The antibody binds to endogenous ras directly, speci®cally at the eector region of the protein which is essential for the activation of its major downstream target, Raf-1 kinase, and which also would be expected to interfere with alternative ras eector molecules. The dominant negative protein binds to and competes for guanine nucleotide exchange factors which are responsible for conversion of p21ras to the active GTP-bound form (Kaplan, 1994) . Our results appear to be consistent with the idea that this nucleotide exchange process, required for cell cycle progression, is largely complete within a relatively short time during G 1 in insulin treated cells, consistent with the kinetic pro®le of ras-bound GTP (Langlois et al., 1994) . However, the interaction of the regulatory domain of Raf-1 with the eector domain of p21ras is GTP dependent (Kolch et al., 1996) and injection of this protein would not be expected to inhibit DNA synthesis late in G 1 unless rasGTP was still present and required, albeit at low concentration. If the persisent inhibition of DNA synthesis observed when anti-ras or dominant negative Raf-1 is microinjected is due to a second late peak of ras activity, this activity appears based on our results to be independent of either Shc or Raf-1.
Because eector domain function of p21ras appears to be required at much later stages in G 1 , this raises the possibility that an alternative eector to Raf-1 is essential for this subsequent function. This ®nding is consistent with recent studies which show that constitutively GTPbound ras is capable of signaling and transformation via Raf-1 independent pathways Khosravi-Far et al., 1996; Kolch et al., 1996; al-Alawi et al., 1995) . The downstream targets of these pathways may be the cell cycle machinery itself, because inactivation of ras causes altered regulation of cyclin D1 and accumulation of the hypophosphorylated, growth-inhibitory form of the Rb protein (Aktas et al., 1997; Peeper et al., 1997) . Downward and coworkers Kodaki et al., 1994) have described a physical interaction between p21ras and PI 3-kinase which requires the ras eector domain, although the signaling relationship between these molecules remains controversial (Hu et al., 1995; Kodaki et al., 1994 Kodaki et al., , 1995 . Also, membrane localization of PI 3-kinase has been shown to be sucient to activate several downstream signaling pathways (Klippel et al., 1996) even at low expression levels. Our results may be a re¯ection of the presence of a complex at later stages in G 1 between p21ras and PI 3-kinase which is dependent upon rasGTP but independent of IRS-1, and which plays an essential role in the cellular commitment to DNA synthesis.
Materials and methods

Maintenance of cell lines
Rat1 ®broblasts overexpressing human insulin receptors (HIRcB cells) were maintained as described previously (McClain et al., 1987) . NIH3T3 cells were maintained in Dulbecco's modi®ed Eagle's medium supplemented with 10% fetal bovine serum and gentamicin. Cells were plated on sterile glass acid-washed coverslips at subcon¯uent density. Before microinjection, cells were rendered quiescent by incubation in serum-free medium for 24 ± 36 h.
Microinjection
All microinjected reagents other than speci®c antibodies contained rabbit IgG (5 mg/ml) to allow the unambiguous identi®cation of injected cells. All reagents were solubilized in microinjection buer consisting of 5 mM NaPO 4 and 100 mM KCl. Approximately 1610 714 liters of sample was introduced into the cytoplasm of each injected cell, resulting in the introduction of 1610 5 to 1610 6 molecules per cell. Injections were carried out using an Eppendorf semiautomated microinjection system. Control injections of preimmune IgG were performed and found not to aect the cell proliferation assay described below. Cells were stimulated with either 100 ng/ml insulin or 100 ng/ml IGF-I 1 h following injection or at the indicated times prior to injection.
Staining and¯uorescence microscopy
To quantitate new DNA synthesis, a solution of 3-bromo-5'deoxyuridine (BrdU) was added to the culture medium for 16 ± 18 h after stimulation. After labeling, coverslips were washed in phosphate-buered saline (PBS), and the cells were then ®xed in 3.7% formaldehyde. After washing, the cells were then incubated with a monoclonal rat anti-BrdU antibody at room temperature. Staining was visualized using rhodamine (TRITC) conjugated donkey anti-rat IgG. Injected cells were visualized using either a¯uorescein (FITC) or aminomethylcoumarin (AMCA) conjugated donkey antibody directed against the microinjected species of IgG. Cells were viewed and the results were analysed on an Axiophot epi¯uorescence microscope equipped with separate ®lters for FITC, TRITC and AMCA. Double exposure photographs were taken on the same equipment using Ektachrome 400 ®lm.
GST fusion protein preparation
The molecular cloning of the fusion proteins used in this study has been described (Jhun et al., 1994b; Kolch et al., 1996) . The p85 fusion protein used (p85N-Sh2) contained residues 321 ± 440 from the p85a subunit of PI 3-kinase, including the N-terminal SH2 domain. The Raf-1 fusion protein used (raf/GNS) contained residues 1 ± 259, including the noncatalytic CR1 region of the protein (Kolch et al., 1996) . Proteins were expressed as GST fusion proteins in Escherichia coli. The proteins were puri®ed from bacterial lysates containing no detergent after treatment of the bacteria with 5 mg/ml lysozyme for 1 h and sonication on ice. Large scale batch puri®cation of the proteins using glutathione-anity chromatography was then accomplished as described (Sasaoka et al., 1994c) . The puri®ed proteins were concentrated and the buer exchanged to microinjection buer using a Centricon 10 unit.
Preparation of anity puri®ed antibodies
Anti-p85a antibody (a gift from Luis Cantley and Lucia Rameh) was generated against a GST-p85 amino-terminal SH2 domain fusion protein. Sera from immunized rabbits were ammonium sulfate precipitated and puri®ed by GST A-Gel 10 chromatography to eliminate anti GST antibodies. The¯ow through from this column was then applied to a GST-p85SH2-N/A-Gel 10 column and anity puri®ed.
Polyclonal anti-IRS-1 antibody (a gift from Alan Saltiel) was raised against amino acid residues 1 ± 224 of rat IRS-1 . Monoclonal anti Raf-1 antibody (URP26K) was raised against amino acid residues 375 ± 678 of murine Raf-1 (Kolch et al., 1990) . Serum or ascites were puri®ed by Protein G agarose chromatography and prepared for microinjection as described.
Monoclonal anti-ras (Y13-259), monoclonal anti-SHP2, and polyclonal anti-Shc antibodies were purchased from commercial sources and prepared for microinjection as described previously Xiao et al., 1994; Sasaoka et al., 1994c) . Dominant negative ras protein (N17) was a gift from Dr James Feramisco and was puri®ed as described (Rose et al., 1992) . It was injected at a concentration of 2 mg/ml.
Assay of phosphatidylinositol 3-kinase activity
HIRcB cells were cultured in 10 cm dishes and grown until 70 ± 80% con¯uent. The cells were then serum starved in HEPES-buered DME for 16 h prior to stimulation with 100 ng/ml insulin for the times indicated. Following stimulation, the medium was rapidly aspirated and the cells were lysed in 500 ml of lysis buer (50 mM HEPES pH 7.4 with 1% Triton X-100; 1 mg/ml Bacitracin; 1 mM PMSF; 1 mM EDTA; 10 mM NaF; 1 mM Na 3 VO 4 ). The lysates were clari®ed by centrifugation at 10 000 g and 20 mg of antiphosphotyrosine antibody (PY20; Transduction Labs, Lexington, KY) were added to the supernatants and incubated overnight at 48C. PY20 was then precipitated using 50 ml antimouse agarose (Sigma Chemical Co, St Louis, MO) for 1 h at 48C. The agarose beads were then washed three times in 1 ml of the following buers: (i) TBS (50 mM Tris; 150 mM NaCl) (not PBSphosphate aects recovery)/1% NP40/Na 3 VO 4 ; (ii) 100 mM Tris pH 7.5/500 mM LiCl 2 /100 mM Na 3 VO 4 ; (iii) 10 mM Tris pH 7.5/100 mM NaCl/1 mM EDTA/100 mM Na 3 VO 4 . The beads were then resuspended in 100 ml 10 mM Tris pH 7.5/ 100 mM NaCl/1 mM EDTA containing 20 mg of L-aphosphatidyl inositol (Avanti Polar Lipids, Birmingham, AL). The reactions were initiated by the addition of [g 32 P]ATP (20 mCi) followed by incubation at room temperature for 10 min. The reactions were terminated by adding 20 ml 8 M HCl and the lipids were extracted using 160 ml CHCl 3 : MeOH (1 : 1). The organic phase was dried down and then spotted onto Silica Gel 60 TLC plates (without¯uorescent indicator) and then developed in chloroform: MEOH : OH : H 2 O (60 : 47 : 2 : 11.3). Labeled phospholipid was visualized by autoradiography at 7708C on pre¯ashed Kodak X-Omat AR ®lm. The amount of phosphorylated product was quanti®ed using a Phosphorimaging screen (Molecular Dynamics) and ImageQuant software.
